Impact of Escitalopram on Sperm DNA Fragmentation
| Status: | Completed |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 3/22/2019 |
| Start Date: | October 1, 2017 |
| End Date: | December 1, 2018 |
Assessing the Impact of Escitalopram on Sperm DNA Fragmentation: A Randomized Placebo Controlled
Double-blind placebo-controlled randomized trial of daily escitalopram for 6 weeks in healthy
men with normal semen analyses and no psychiatric history of depression, bipolar, mania or
suicidal ideation. Hormone profiles, semen analysis, sperm DNA fragmentation, and sexual
function will be measured at baseline, after 6 weeks of therapy, and 4 weeks after
discontinuation of therapy (10 weeks into study).
men with normal semen analyses and no psychiatric history of depression, bipolar, mania or
suicidal ideation. Hormone profiles, semen analysis, sperm DNA fragmentation, and sexual
function will be measured at baseline, after 6 weeks of therapy, and 4 weeks after
discontinuation of therapy (10 weeks into study).
SSRI medications, specifically escitalopram is a very commonly prescribed medication among
men of reproductive age. Significant evidence exists that they may be harmful for paternal
fertility potential in both animal and human studies. However, high quality data is lacking,
particularly among commonly used SSRI's such as escitalopram. As such, it is important to
properly evaluate the potential effect of escitalopram in a randomized placebo controlled
fashion. Results will be important in guiding urologists, psychiatrists and family
practitioners regarding discussion surrounding SSRI use in their patients interested in
fertility.
men of reproductive age. Significant evidence exists that they may be harmful for paternal
fertility potential in both animal and human studies. However, high quality data is lacking,
particularly among commonly used SSRI's such as escitalopram. As such, it is important to
properly evaluate the potential effect of escitalopram in a randomized placebo controlled
fashion. Results will be important in guiding urologists, psychiatrists and family
practitioners regarding discussion surrounding SSRI use in their patients interested in
fertility.
Inclusion Criteria:
- Normal semen analyses, or semen analyses with at least 5 million sperm
- Normal TUNEL value (<7%)
- Willing to engage in at least weekly sexual activity, with a partner or alone for the
duration of the 10-week study
Exclusion Criteria:
- Azoospermia or severe oligospermia (<5million sperm per semen analysis)
- Presently attempting to conceive pregnancy
- Sexual dysfunction preventing ability to provide semen analysis throughout study or
engage in weekly sexual activity
- Current psychiatric disorder including: bipolar, mania, depression, generalized
anxiety, social phobia, panic attacks, obsessive compulsive disorder, and
schizophrenia.
- Family history of bipolar disorder, or suicide (including 2nd degree relatives)
- Present use of psychotropic agents (prescription or herbal) or anticonvulsants
- Use of sleeping pills
- Alcohol consumption greater that 2oz/day
- Use of illicit drugs
- Inability to read, follow instructions or complete questionnaires in English.
- Use of hormonal medications in past 3 months (androgens, androgen blockade, anabolic
steroids, estrogens, herbal)
- Use of medications to enhance sexual function
- History of chemotherapy or pelvic radiation
- Use of Monoamine Oxidase inhibitors (MAOi's) or tricyclic antidepressants (TCAs)
within 14 days
- Liver disease
We found this trial at
1
site
Click here to add this to my saved trials
